The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Scuba Doc

Forum Topics Started

Viewing 6 topics - 1 through 6 (of 6 total)

- TOPIC
- Nivolumab as first-line treatment
  Started by: Scuba Doc General Melanoma Community
- 3
- 15
- JerryfromFauq
  
  10 years, 8 months ago
- Oncologists want PD-1 as first line treatment
  Started by: Scuba Doc General Melanoma Community
- 0
- 0
- Scuba Doc
  
  10 years, 9 months ago
- MK-3475 Approval?
  Started by: Scuba Doc General Melanoma Community
- 5
- 24
- Cooper
  
  10 years, 10 months ago
- Expanded Access Program for MK-3475
  Started by: Scuba Doc General Melanoma Community
- 2
- 6
- Bubbles
  
  11 years ago
- Early Access Program for MK-3475
  Started by: Scuba Doc General Melanoma Community
- 1
- 3
- arthurjedi007
  
  11 years, 1 month ago
- Novartis–LEE011
  Started by: Scuba Doc General Melanoma Community
- 3
- 24
- POW
  
  11 years, 1 month ago

Viewing 6 topics - 1 through 6 (of 6 total)

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.